Myriad Genetics MYGN reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM.
Here's what investors need to know about the announcement.
Earnings
Myriad Genetics beat estimated earnings by 57.14%, reporting an EPS of $-0.03 versus an estimate of $-0.07.
Revenue was down $8.20 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0 which was followed by a 3.06% drop in the share price the next day.
Here's a look at Myriad Genetics's past performance:
Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
---|---|---|---|---|
EPS Estimate | -0.02 | -0.02 | -0.09 | -0.14 |
EPS Actual | -0.02 | -0.02 | 0.12 | -0.06 |
Revenue Estimate | 163.40M | 165.04M | 165.39M | 156.20M |
Revenue Actual | 160.80M | 167.30M | 189.40M | 173.10M |
To track all earnings releases for Myriad Genetics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.